Revelation Biosciences Inc

0
STU:56U0 (USA)   Ordinary Shares
€ 10.62 (0%) Nov 5
At Loss
P/B:
1.22
Market Cap:
€ 3.03M ($ 3.24M)
Enterprise V:
€ 8.75M ($ 9.36M)
Volume:
-
Avg Vol (2M):
-
Trade In:

Business Description

Revelation Biosciences Inc
NAICS : 541715 SIC : 2834
ISIN : US76135L5075

Share Class Description:

STU:56U0: Ordinary Shares
Description
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.09
Interest Coverage No Debt
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
Future 3-5Y EPS without NRI Growth Rate Estimate 51.87

Momentum Rank

Name Current Vs Industry Vs History
14-Day RSI 34.35
12-1 Month Momentum % -34.44

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.1
Quick Ratio 1.1
Cash Ratio 1.08

Dividend & Buy Back

Name Current Vs Industry Vs History
Shareholder Yield % -170.03
Name Current Vs Industry Vs History
ROE % -212.05
ROA % -114.5
ROIC % -338.57
ROC (Joel Greenblatt) % -13123.97
ROCE % -127.05

Financials

STU:56U0's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Revelation Biosciences Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €)
EPS (TTM) (€) -26.471
Beta 0
Volatility % 46.43
14-Day RSI 34.35
14-Day ATR (€) 0.000007
20-Day SMA (€) 10.62
12-1 Month Momentum % -34.44
52-Week Range (€) 9.06 - 20.55
Shares Outstanding (Mil) 3.76

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Revelation Biosciences Inc Filings

Filing Date Document Date Form
No Filing Data

Revelation Biosciences Inc Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

Revelation Biosciences Inc Frequently Asked Questions

What is Revelation Biosciences Inc(STU:56U0)'s stock price today?
The current price of STU:56U0 is €10.62. The 52 week high of STU:56U0 is €20.55 and 52 week low is €9.06.
When is next earnings date of Revelation Biosciences Inc(STU:56U0)?
The next earnings date of Revelation Biosciences Inc(STU:56U0) is .
Does Revelation Biosciences Inc(STU:56U0) pay dividends? If so, how much?
Revelation Biosciences Inc(STU:56U0) does not pay dividend.

Press Release

Subject Date
No Press Release